Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

Is it smart to be bullish on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

At the moment, there are tons of metrics shareholders can use to monitor their holdings. A couple of the most under-the-radar are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the top picks of the elite investment managers can trounce their index-focused peers by a very impressive margin (see just how much).

Just as useful, bullish insider trading sentiment is another way to analyze the marketplace. Just as you’d expect, there are lots of motivations for an upper level exec to cut shares of his or her company, but only one, very obvious reason why they would buy. Several academic studies have demonstrated the impressive potential of this strategy if investors know what to do (learn more here).

Thus, it’s important to examine the recent info about Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

How have hedgies been trading Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

Heading into Q3, a total of 10 of the hedge funds we track were long in this stock, a change of -38% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were boosting their holdings considerably.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)Out of the hedge funds we follow, RA Capital Management, managed by Peter Kolchinsky, holds the biggest position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS). RA Capital Management has a $24.5 million position in the stock, comprising 3.2% of its 13F portfolio. Coming in second is Visium Asset Management, managed by Jacob Gottlieb, which held a $21.2 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Other hedge funds with similar optimism include Israel Englander’s Millennium Management, Andrew J. M. Spokes’s Farallon Capital and Richard Driehaus’s Driehaus Capital.

Because Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has experienced bearish sentiment from the smart money’s best and brightest, it’s safe to say that there is a sect of hedge funds that elected to cut their positions entirely in Q1. Interestingly, Mark Broach’s Manatuck Hill Partners dropped the largest position of all the hedgies we key on, valued at close to $1.5 million in stock. Louis Bacon’s fund, Moore Global Investments, also cut its stock, about $0.7 million worth. These moves are interesting, as total hedge fund interest was cut by 6 funds in Q1.

How have insiders been trading Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)?

Insider buying is best served when the company in question has seen transactions within the past 180 days. Over the latest half-year time frame, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll also review the relationship between both of these indicators in other stocks similar to Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS). These stocks are Curis, Inc. (NASDAQ:CRIS), Repros Therapeutics Inc (NASDAQ:RPRX), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), XOMA Corp (NASDAQ:XOMA), and Cerus Corporation (NASDAQ:CERS). This group of stocks belong to the biotechnology industry and their market caps are similar to SNSS’s market cap.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.